Omid Farokhzad Sells 8,068 Shares of Seer, Inc. (NASDAQ:SEER) Stock

Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad sold 8,068 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.24, for a total transaction of $18,072.32. Following the transaction, the chief executive officer now directly owns 1,428,217 shares of the company’s stock, valued at approximately $3,199,206.08. This trade represents a 0.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Seer Stock Up 2.2 %

NASDAQ:SEER opened at $2.33 on Friday. The firm’s fifty day moving average is $2.37 and its two-hundred day moving average is $2.07. Seer, Inc. has a one year low of $1.51 and a one year high of $2.63.

Hedge Funds Weigh In On Seer

Several institutional investors have recently made changes to their positions in the company. Barclays PLC boosted its holdings in Seer by 34.1% during the third quarter. Barclays PLC now owns 64,426 shares of the company’s stock worth $127,000 after buying an additional 16,382 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Seer in the third quarter worth about $123,000. Geode Capital Management LLC boosted its stake in shares of Seer by 5.9% during the 3rd quarter. Geode Capital Management LLC now owns 446,329 shares of the company’s stock worth $879,000 after acquiring an additional 25,002 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Seer by 67.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 175,354 shares of the company’s stock valued at $345,000 after acquiring an additional 70,671 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Seer in the 2nd quarter valued at about $133,000. 75.20% of the stock is owned by hedge funds and other institutional investors.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.